Christopher Haas, MD
Dermatology · Shreveport, LANPI 1821520115
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,600 of the $48,787 with a category attached, or 64.8%. AbbVie accounts for 70.2% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $28,659, more than ten times the $13 reported in 2019. Among dermatology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $216.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Johnson & Johnson$7K
- E.r. Squibb & Sons, L.L.C.$3K
- Sanofi$673
- Novartis$486
- Lilly USA, LLC$430
- plus $3K from 18 others
What the payments were for
- Consulting fees$8,87318%
- Speaking & faculty fees$31,60065%
- Travel & lodging$1,8134%
- Food & beverage$6,27113%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $34,251 |
| Johnson & Johnson | 10 | $7,332 |
| E.r. Squibb & Sons, L.L.C. | 13 | $3,067 |
| Sanofi | 16 | $673 |
| Novartis | 26 | $486 |
| Lilly USA, LLC | 20 | $430 |
| Galderma Laboratories, L.p. | 7 | $348 |
| UCB, Inc. | 6 | $343 |
| Amgen | 10 | $306 |
| Incyte Corporation | 8 | $235 |
| Regeneron Healthcare Solutions, Inc. | 8 | $230 |
| LEO Pharma Inc. | 7 | $215 |
| Sun Pharmaceutical Industries Inc. | 8 | $186 |
| Pfizer | 3 | $159 |
| Botanix SB Inc | 1 | $142 |
| Kyowa Kirin, Inc. | 2 | $112 |
| Melinta Therapeutics, LLC | 1 | $62 |
| Boehringer Ingelheim | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Triad Life Sciences Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,787 in reported general payments places this provider in the 90th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Shreveport
- Katherine HolcombMetairie$411K
- William ClaiborneNew Orleans$374K
- Blair BuddenLafayette$329K
- Erin BohNew Orleans$277K
- Mara HaseltineNew Orleans$276K
- Sarah HaydelHouma$265K
- Frankie RholdonLafayette$227K
- William MassengalePrairieville$225K
- Julie MermilliodNew Orleans$222K
- Robert KoppelMetairie$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.